Supply Chain Intelligence

Lantern Pharma Inc. Supply Chain

LTRN supply chain intelligence for Lantern Pharma Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

LTRN ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

14Suppliers
4Customers
2Debt Items
20Related Chains

Lantern Pharma Inc. Suppliers

TickerNameConfidenceEvidence
BERKSHIRE-STERILE-MANUFACTURING BERKSHIRE-STERILE-MANUFACTURING 92% We have contracted with Berkshire Sterile Manufacturing for the provision of services relating to cGMP drug product manufacturing of LP-300.
CURIA-GLOBAL-INC CURIA-GLOBAL-INC 92% We have contracted with Curia Global, Inc. for the manufacture and supply of LP-300 cGMP API material.
PIRAMAL-PHARMA-SOLUTIONS PIRAMAL-PHARMA-SOLUTIONS 92% We have contracted with Piramal Pharma Solutions for the provision of services relating to cGMP drug product manufacturing of LP-300.
SHILPA-MEDICARE-LIMITED SHILPA-MEDICARE-LIMITED 92% We have contracted with Shilpa Medicare Limited and affiliates for the cGMP synthesis of LP-184 API material as well as for drug product development and cGMP drug product manufacturing of LP-184.
ACTUATE-THERAPEUTICS ACTUATE-THERAPEUTICS 90% The Company and Actuate have collaborated on utilization of the Company’s RADR ® platform to develop novel biomarker derived signatures for use with one of Actuate’s product candidates.
BIONUMERIK-PHARMACEUTICALS-INC BIONUMERIK-PHARMACEUTICALS-INC 90% LP-300 is a small molecule that was in-licensed from BioNumerik Pharmaceuticals, Inc. in May 2016, and subsequently acquired by us in 2018.
SIEGFRIED-ACCELERATION-HUB SIEGFRIED-ACCELERATION-HUB 90% In 2025, the Curia site where the LP-300 API is manufactured changed its name to Siegfried Acceleration Hub, reflecting the acquisition of the manufacturing site by the Siegfried Group.
THINKEQUITY-LLC THINKEQUITY-LLC 90% On May 12, 2026, the Company suspended offers and sales of the shares of Common Stock pursuant to the prospectus supplement, dated July 3, 2025, relating to the ATM Sales Agreement, dated July 3, 202…
ACTUATE-THERAPEUTICS-INC ACTUATE-THERAPEUTICS-INC 85% Pursuant to the agreement, we collaborated on utilization of our RADR ® platform to develop novel biomarker derived signatures for use with one of Actuate's product candidates.
BIELEFELD-UNIVERSITY BIELEFELD-UNIVERSITY 85% In 2023, we entered into a research collaboration with Bielefeld University in Germany focused on development of ADCs utilizing cryptophycin as the ADC drug-payload.
TTC-ONCOLOGY TTC-ONCOLOGY 85% In February 2023, we entered into a Collaboration Agreement with TTC Oncology.
ZETA-AI ZETA-AI 80% plans to create an independent business entity composed of the AI platform, with Zeta.ai, and related technologies and personnel under the leadership of CEO Mr. Panna Sharma
JNJ Johnson & Johnson 72% the US, Australia, Canada, EU, China, and Japan. LP-300 Our portfolio directed to LP-300 consists of at least four families of owned patents. A more recent PCT patent application filed in 2020 is dir…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from LTRN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from LTRN graph: Reciprocal relationship from JNJ grap…

Lantern Pharma Inc. Customers

TickerNameConfidenceEvidence
ALLARITY-THERAPEUTICS-A-S ALLARITY-THERAPEUTICS-A-S 90% LP-100 was previously out-licensed by us to Allarity Therapeutics A/S.
TRIVIUMVET-DAC TRIVIUMVET-DAC 90% We will provide TriviumVet DAC with (i) specified data and information generated by us with respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark r…
JNJ Johnson & Johnson 72% the US, Australia, Canada, EU, China, and Japan. LP-300 Our portfolio directed to LP-300 consists of at least four families of owned patents. A more recent PCT patent application filed in 2020 is dir…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from LTRN graph: the US, Australia, Canada, EU, China, and Japan. LP-300 Our portfolio directed to LP-300 consists of at least four fam…

Lantern Pharma Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LTRN-DEBT-10812 Warrants outstanding: 86685 90% xbrl warrant detail from xbrl 2024-12-31.
LTRN-DEBT Debt stack $59,076 90% Market cache reports total debt of $59,076.

Lantern Pharma Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lantern Pharma Inc..

Lantern Pharma Inc. Ownership

HolderNameConfidenceEvidence
LTRN-OWNER-BIOS-CAPITAL-MANAGEMENT-LP BIOS Capital Management, LP 90% 13F overlay lists BIOS Capital Management, LP as top holder; 32 tracked holders.

Lantern Pharma Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
JNJ Johnson & Johnson 100.00 1 ['customer', 'supplier']
CYCN Cyclerion Therapeutics, Inc. 50.00 2
SI Shoulder Innovations, Inc. 50.00 2
CYTOF Altamira Therapeutics Ltd. 50.00 2
ANIK Anika Therapeutics, Inc. 50.00 2
AORT Artivion, Inc. 50.00 2
AVBP ArriVent BioPharma, Inc. 50.00 2
CBIH Cannabis Bioscience International Holdings, Inc. 50.00 2
BNR Burning Rock Biotech Limited 50.00 2
BNRG Brenmiller Energy Ltd 50.00 2
AVTX Avalo Therapeutics, Inc. 50.00 2
CSTE Caesarstone Ltd. 50.00 2
DYAI Dyadic International, Inc. 50.00 2
SNNUF Smith & Nephew plc 50.00 2
CVRX CVRx, Inc. 50.00 2
ALC Alcon Inc. 50.00 2
ATRA Atara Biotherapeutics, Inc. 50.00 2
SYRE Spyre Therapeutics, Inc. 50.00 2
EVFM Evofem Biosciences, Inc. 50.00 2
BLLN BillionToOne, Inc. 50.00 2
View LTRN supply chain intel →

Explore the full interactive supply chain map for Lantern Pharma Inc..

Open LTRN supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map